TOKYO—Biogen Inc.’s chief executive said investors overreacted when they pushed down the company’s share price nearly 7% on news that it was adding patients to trials of an Alzheimer’s disease drug. “It’s very common that we have to increase the sample size, and we don’t take that as a sign that influences whatsoever the outcome of the study,” said Michel Vounatsos, head of the Cambridge, Mass., drugmaker, in an interview on a visit to Japan, where Biogen is trying to expand its presence.

Source: Wall Street Journal February 20, 2018 09:22 UTC